Positive Predictive Value

Shows how a test’s positive predictive value depends on disease prevalence, not just its sensitivity and specificity.
Author

Apurva Nakade

Published

August 1, 2026

A screening mammogram in U.S. community practice has about 87% sensitivity and 92% specificity (Lee et al., 2023): if you have cancer it comes back positive 87% of the time, and if you don’t, it comes back negative 92% of the time. About 7 in 1,000 women screened have breast cancer.

If you test positive, what are the chances you have the condition? This is the test’s positive predictive value (PPV). Make a guess before reading on — the answer may surprise you.

The answer

At the default settings that’s about 7%, far lower than most people guess. When a condition is rare, the healthy group is so much larger that even a small false-positive rate among them outnumbers the true positives among the few who are sick: a handful of red in a crowd of dark.

Doctors get it wrong too

If you guessed high, you’re in good company. When researchers asked 60 staff and students at Harvard Medical School about a disease with a prevalence of 1 in 1,000 and a test with a 5% false-positive rate, nearly half answered 95%; only 11 gave the correct answer, about 2% (Casscells, Schoenberger & Graboys, 1978). In a mammography version of the question, most physicians estimated about 75% when the answer was 7.5% (Eddy, 1982). Judging a positive by the test’s accuracy alone, while ignoring how rare the condition is, is called the base-rate fallacy.

How the numbers are presented matters. Given percentages, only 10% of physicians answered correctly; given the same numbers as natural frequencies (“10 out of 1,000 women…”), 46% did (Hoffrage & Gigerenzer, 1998). That’s why this page shows 1,000 people as dots.

Why retesting helps

A second test goes only to the people who tested positive, and among them the condition is far more common: its prevalence is the first test’s PPV. The same test, applied to that group, gives a much higher PPV, as the Tests slider and the summary table show. Bayes’ rule is this update, with the denominator split into the two ways a test can come back positive:

\[ \begin{aligned} P(\text{condition} \mid \text{positive}) &= \frac{P(\text{positive} \mid \text{condition})\, P(\text{condition})}{P(\text{positive})} \\[0.6em] &= \frac{P(\text{positive} \mid \text{condition})\, P(\text{condition})} {P(\text{positive} \mid \text{condition})\, P(\text{condition}) + P(\text{positive} \mid \text{no condition})\, P(\text{no condition})} \\[0.6em] &= \frac{\text{true positives}}{\text{true positives} + \text{false positives}}. \end{aligned} \]

Screening in practice

A positive mammogram is not a diagnosis; it starts a three-round process that works the same way, with the PPV out of each round becoming the prevalence going into the next.

Screening mammogram flags about 8% of women for a closer look (recall)

Diagnostic imaging additional views, ultrasound or MRI clear about four in five of those recalled

Biopsy confirms cancer in about a third of the remaining cases

Per 1,000 women screened in Lee et al.’s data, 83 are recalled, about 18 go on to biopsy, and 6 have cancer: the PPV rises from 7% after the mammogram to 32% after biopsy.

Same test, different population

At the height of the pandemic, COVID-19 prevalence reached 32.6%; today it is under 1%. Slide Prevalence , then , leaving Sensitivity and Specificity where they are. What happens to the PPV?

Now suppose you ran a study today, found that most people who tested positive did not have COVID-19, and reported that the test is bad. Is that a valid claim?

References

  • Casscells, W., Schoenberger, A., & Graboys, T. B. (1978). Interpretation by Physicians of Clinical Laboratory Results. New England Journal of Medicine, 299(18), 999–1001. https://doi.org/10.1056/NEJM197811022991808.
  • Eddy, D. M. (1982). Probabilistic Reasoning in Clinical Medicine: Problems and Opportunities. In D. Kahneman, P. Slovic, & A. Tversky (Eds.), Judgment under Uncertainty: Heuristics and Biases (pp. 249–267). Cambridge University Press. https://doi.org/10.1017/CBO9780511809477.019.
  • Hoffrage, U., & Gigerenzer, G. (1998). Using Natural Frequencies to Improve Diagnostic Inferences. Academic Medicine, 73(5), 538–540. https://doi.org/10.1097/00001888-199805000-00024.
  • Lee, C. I., Abraham, L., Miglioretti, D. L., Stout, N. K., Kerlikowske, K., Henderson, L. M., Tosteson, A. N. A., Bissell, M. C. S., Onega, T., Sprague, B. L., Sabatino, S. A., Lawson, M. B., Lowry, K. P., Buist, D. S. M., & Breast Cancer Surveillance Consortium (2023). National Performance Benchmarks for Screening Digital Breast Tomosynthesis: Update from the Breast Cancer Surveillance Consortium. Radiology, 307(4), e222499. https://doi.org/10.1148/radiol.222499. Source of this page’s sensitivity (87.4%), specificity (92.2%) and prevalence (5.8 cancers detected plus 0.8 missed per 1,000 screens), plus the recall rate (8.3%) and the PPV after screening (6.9%) and after biopsy (32.2%), from 458,175 U.S. screening examinations, 2011–2018.